SAN FRANCISCO, June 18, 2019Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Jason Coloma, Ph.D., Maze’s current chief operating officer, has been appointed as chief executive officer. He succeeds interim CEO, Charles Homcy, M.D., who will assume the role of chairman of the company’s board of directors. In addition, Maze announced the appointment of Matt Krause, a nearly 25-year human resources leader, as senior vice president of human resources.

Jason has been instrumental in the success of Maze. We are thrilled that he will continue to lead the company as CEO.

“Beginning with the initial idea for the company, through our launch to today, Jason has been instrumental in the success of Maze. We are thrilled that he will continue to lead the company as CEO,” said Dr. Homcy. “As we look ahead, Maze is focused on leveraging our expertise in human genetics and functional genomics to create important new medicines for a number of diseases. To be successful, we will need to continue hiring the best minds in the industry, and we look forward to leveraging Matt’s experience to build a unique and diverse company. Maze is built on world-class science, and as chairman of the board of directors, I’m excited to continue to participate in its evolution.”

“Since launching earlier this year, the Maze team has made tremendous progress advancing our approach of translating genetic insights into new therapeutics,” said Dr. Coloma. “I am very excited about the potential of Maze to make a difference in the future of human health and medicine, which contributed to my decision to leave Third Rock and join Maze as full-time CEO. We are thankful to Charles and all that he has done to bring Maze from an idea to a reality, and look forward to continuing our work together with him leading our board of directors.”

About Dr. Jason Coloma

Prior to joining Maze, Dr. Coloma was a venture partner at Third Rock Ventures, where he focused on new company formation. He has also held interim chief business officer roles with Third Rock portfolio companies insitro and Celsius. Prior to joining Third Rock, Dr. Coloma was the senior vice president and chief business officer at Corvus Pharmaceuticals. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Dr. Coloma was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Dr. Coloma holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.

About Matt Krause

Mr. Krause has spent his nearly 25-year career in human resources helping companies build experienced teams. He joins Maze from Global Blood Therapeutics where he served as vice president of human resources and helped build out the team starting from company formation through clinical development. Prior to Global Blood, Mr. Krause held a number of senior director and representative roles in human resources, including at Audience, Inc., Amyris Biotechnology, CV Therapeutics, CopperCom, Gilead Sciences, Bio-Rad Laboratories and DNA Plant Technology. Mr. Krause holds an M.S. in industrial relations from the University of Oregon and received a B.S. in business administration and finance from California State University, Long Beach.

About Maze Therapeutics

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas, coupled with deep biological insights and advanced data science tools, have enabled Maze to understand the ways modifier genes can confer protection. Maze will create therapies that mimic protective modifiers. The company was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. For more information please visit

Media Contact

Katie Engleman, 1AB